UNSPSC 51111707: Deoxycoformycin or pentostatin

This classification denotes an adenosine deaminase inhibitor with the molecular formula C11H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 395575MZO7, chemically known as (r)-3-(2-deoxy-beta-d-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol but generally known as pentostatin, which bears US NIH Compound Identifier 40926. European Medicines Agency schedules Pentostatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09704MIG.

UNSPSC 51111707 Deoxycoformycin or pentostatin is a Commodity code that captures pharmaceutical procurement under specialty cancer chemotherapy agents, though recent state and local activity shows limited direct solicitation specific to this molecule. The single identified opportunity reflects broader state health agency interest in restructuring pharmaceutical supply and pricing models rather than acquisition of the drug itself as a standalone commodity.

The Texas Health and Human Services Commission issued Request for Information No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI solicits information about vendors' capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, operate outside traditional pharmacy benefit manager and group purchasing organization channels, and structure contracts around negotiated net pricing without rebates. The procurement focuses on vendors' experience with direct contracting for self-insured employers and government health plans, ability to fulfill product volume requirements, and participation in purchasing organizations serving multiple government jurisdictions. As a preliminary market-intelligence mechanism rather than a formal competitive solicitation, the RFI carries no award value, budget range, set-aside designation, or binding timeline; Texas HHS intends to use vendor responses to inform detailed procurement specifications and implementation strategy for subsequent formal solicitations. The absence of other recent state or local opportunities under this code suggests the pharmaceutical supply landscape is shifting toward consolidated purchasing and direct manufacturer relationships rather than transaction-level acquisition of specific drugs.